Skip to main content
OpenTrials
Completed

NCT Number: NCT03253926

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cannabis Use

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

New York State Psychiatric Institute

New York, 10032, United States

About this study

In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non treatment-seeking cannabis smokers. In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current cannabis use
  • Able to give informed consent and perform study procedures
  • Women practicing an effective form of birth control
  • English speaking

Exclusion criteria

  • Presence of any clinically significant medical diagnoses
  • History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes
  • Current parole or probation
  • Certain psychiatric diagnoses
  • Current pregnancy or lactation

Treatment and study plan

Lorcaserin

Drug

Lorcaserin 10mg BID

Placebo

Drug

Placebo capsule BID

Marijuana

Drug

Smoked marijuana cigarette

Primary outcomes

  1. Cannabis Self-administration

    Time frame: 14 days

    Number of cannabis puffs participant chooses to smoke.

Sponsors and collaborators

Lead sponsor

New York State Psychiatric Institute

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Aug 18, 2017
Registry last updated
Jul 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.